We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Solution Used to Store Donated Blood Platelets

By LabMedica International staff writers
Posted on 28 Dec 2009
A platelet additive solution, in combination with human plasma, is being used to store donated platelets, a vital blood component used to prevent or treat bleeding.

The InterSol additive is an isotonic solution designed to replace a portion of the plasma used in the storage of leuko-reduced apheresis platelets, under standard blood banking conditions. More...
The platelets can be stored in a mixture of up to 65% InterSol solution and 35% human plasma, which can then be used for other therapeutic purposes. There is no direct therapeutic effect to be expected from the formulation, and the solution should never be infused directly into a patient. The InterSol solution is provided as a 500 ml sterile and nonpyrogenic solution in a non-PVC plastic container, with a sterile fluid path. Platelets prepared with the solution may be stored for up to 5 days at 20 °C to 24 °C, with continuous agitation.

The solution contains constituents that are naturally occurring components present in many cellular systems: sodium acetate as a nutrient, sodium citrate to prevent platelet clumping and activation, sodium phosphate for buffering, and sodium chloride for osmolarity. The InterSol solution does not have a pharmacological effect in vivo, but rather acts to provide the appropriate environment and nutrients in lieu of a portion of the plasma normally used for the storage of platelets. The InterSol solution is a product of Fenwal Blood Technologies (Lake Zurich, IL, USA), and has been approved for use by the U.S. Food and Drug Administration exclusively with platelets collected using the Fenwal Amicus separator, a medical device that collects platelets and other blood components from eligible donors.

"FDA approval for the InterSol solution is an exciting milestone for Fenwal and represents our collaboration with customers, industry, and scientific leaders to introduce new ways to collect, process, and store blood for transfusion,” said William H. Cork, Fenwal senior vice president and chief technology officer (CTO).

Refrigerated platelets have better in vitro function than those stored at room temperature, but once transfused, they are rapidly cleared from the circulation. In 1981, platelet storage at room temperature was extended from 3 days to 5 days due to improved platelet storage bags that allowed more efficient gas exchange. However, with the extended storage at room temperature, bacterial proliferation became a significant problem and an increased number of platelet transfusion-associated sepsis reactions occur.

Related Links:
Fenwal Blood Technologies




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sample Transportation System
Tempus1800 Necto
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.